Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Afroditi Karathanasi"'
Autor:
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis
Publikováno v:
Drugs in R&D, Vol 20, Iss 2, Pp 55-73 (2020)
Abstract Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic le
Externí odkaz:
https://doaj.org/article/d86397648f6f4e27a7986f7cef885935
Publikováno v:
Diseases, Vol 9, Iss 2, p 34 (2021)
Cancer-associated thrombosis (CAT) is a rising and significant phenomenon, becoming the second leading cause of death in cancer patients. Pathophysiology of CAT differs from thrombosis in the non-cancer population. There are additional risk factors f
Externí odkaz:
https://doaj.org/article/bc6bc1687fc64235bb4a1473f98d477e
Autor:
Stergios Boussios, Peeter Karihtala, Michele Moschetta, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis
Publikováno v:
Diagnostics, Vol 9, Iss 3, p 87 (2019)
Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to a major change in the treatment of adva
Externí odkaz:
https://doaj.org/article/17279f479d6a438fb867fdf6bbfad125
Autor:
Stergios Boussios, Afroditi Karathanasi, Deirdre Cooke, Cherie Neille, Agne Sadauskaite, Michele Moschetta, Nikolaos Zakynthinakis-Kyriakou, Nicholas Pavlidis
Publikováno v:
Diagnostics, Vol 9, Iss 2, p 55 (2019)
Poly (ADP-ribose) polymerase (PARP) inhibitors are a novel class of therapeutic agents that target tumors with deficiencies in the homologous recombination DNA repair pathway. Genomic instability characterizes high-grade serous ovarian cancer (HGSOC)
Externí odkaz:
https://doaj.org/article/555c822c7723436e99dc6ed3dea5e361
Publikováno v:
Diseases
Diseases, Vol 9, Iss 34, p 34 (2021)
Diseases, Vol 9, Iss 34, p 34 (2021)
Cancer-associated thrombosis (CAT) is a rising and significant phenomenon, becoming the second leading cause of death in cancer patients. Pathophysiology of CAT differs from thrombosis in the non-cancer population. There are additional risk factors f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9223ab9af6d5e78c1ed75252b0fcd08
https://pubmed.ncbi.nlm.nih.gov/34064390
https://pubmed.ncbi.nlm.nih.gov/34064390
Autor:
Nicholas Pavlidis, Peeter Karihtala, Mehmet Akif Ozturk, Afroditi Karathanasi, Stergios Boussios, Matin Sheriff, Eleftherios P. Samartzis, Elie El Rassy, George Pappas-Gogos, Mario Uccello, Michail Tringos, Michele Moschetta
Publikováno v:
Ann Transl Med
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women, potentially due to ineffectiveness of screening tests for early detection. Patients typically present with advanced disease at diagnosis, whereas, up to 80% r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f330a1de401262e47cd0c8efd4ee00
https://www.zora.uzh.ch/id/eprint/199041/
https://www.zora.uzh.ch/id/eprint/199041/
Autor:
Jake, E Ryan, Vijayakumar, Ganesh, Afroditi, Karathanasi, Michele, Moschetta, Matin, Sheriff, John, B Schofield, Stergios, Boussios
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 25(2)
Langerhans cell histiocytosis (LCH) is disease process characterized by clonal proliferation of CD1a+ dendritic cells within an inflammatory infiltrate of hematopoietic derived cells. LCH can manifest with a broad spectrum of symptoms and can involve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85f0cccd47ed3be59c2fade90aab2e8b
https://pubmed.ncbi.nlm.nih.gov/32521842
https://pubmed.ncbi.nlm.nih.gov/32521842
Autor:
Matin Sheriff, Christos Mikropoulos, Stergios Boussios, Elie El Rassy, Peeter Karihtala, Afroditi Karathanasi, Agne Sadauskaite, Eleftherios P. Samartzis, Nicholas Pavlidis, Michele Moschetta
Publikováno v:
Journal of Personalized Medicine
Journal of Personalized Medicine, Vol 10, Iss 41, p 41 (2020)
Journal of Personalized Medicine, Vol 10, Iss 41, p 41 (2020)
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women. Two-thirds of patients present at advanced stage at diagnosis, and the estimated 5 year survival rate is 20–40%. This heterogeneous group of malignancies ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d1f3b9243a8c5b4e1b5d7302e9220c8
https://www.repository.cam.ac.uk/handle/1810/305714
https://www.repository.cam.ac.uk/handle/1810/305714
Autor:
Nicholas Pavlidis, Michele Moschetta, Jake Edward Ryan, Elie El Rassy, Nikolaos Zakynthinakis-Kyriakou, Charlotte Abson, Stergios Boussios, Afroditi Karathanasi, Matin Sheriff, Peeter Karihtala
Publikováno v:
Investigational new drugs. 38(1)
Epithelial ovarian cancer (EOC) accounts for nearly 90% of all ovarian malignancies. The standard therapeutic strategy includes cytoreductive surgery and neo (adjuvant) platinum-based chemotherapy. Relapse of advanced high grade serous ovarian cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a76021c34155ad4b5418696e661ea2
https://pubmed.ncbi.nlm.nih.gov/31650446
https://pubmed.ncbi.nlm.nih.gov/31650446
Autor:
Elie El Rassy, Afroditi Karathanasi, Peeter Karihtala, Nicholas Pavlidis, Stergios Boussios, Michele Moschetta, Agne Sadauskaite
Publikováno v:
Diagnostics, Vol 9, Iss 3, p 87 (2019)
Diagnostics
Diagnostics
Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to a major change in the treatment of adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2a840d9140913f01eb08e0cac5b570a
https://www.mdpi.com/2075-4418/9/3/87
https://www.mdpi.com/2075-4418/9/3/87